|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered Ⅳ daily X 5 every other week in patients (pts) with refractory or advanced malignanciSs显示文摘 | Mita MM Rowinsky EK Goldston ML | 2004 | Clin Oncol2004，30，3： | 1 |
| 2 | Taxol:a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms显示文摘 | McGuire WP Rowinsky EK Rosenshein NB | 1989 | Ann Intern Med1989，111，4： | 1 |
| 3 | Neurotoxicity of taxol显示文摘 | Rowinsky EK Chaudhry V Cornblath DR | 1993 | J Natl Cancer Inst Monogr1993，15，： | 1 |
| 4 | The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents 显示文摘 | Rowinsky EK | 2000 | Drugs2000，60，1： | 1 |
| 5 | Paclitaxel in cancer treatment显示文摘 | McGuire WP Rowinsky EK | 1995 | Marcel Dekker Inc USA1995，3540，： | 1 |
| 6 | Phase Ⅰ and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory aucte leukemia显示文摘 | Rowinsky EK Adjiei R Donehower RC | 1994 | J Clin Oncol1994，12，： | 1 |
| 7 | Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI -774 in human epidermis of cancer patients 显示文摘 | Malik SN Siu LL Rowinsky EK | 2003 | Clin Cancer Res2003，9，： | 1 |
| 8 | Vascular endothelial growth factor receptor-1 in human cancer:concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1)显示文摘 | Schwartz JD Rowinsky EK Youssoufian H | | 0，，： | 1 |
| 9 | Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms 显示文摘 | MCGUIRE WP ROWINSKY EK ROSENSHEIN NB | 1989 | Annals of Internal Medicine1989，111，4： | 1 |
| 10 | A phase Ⅱ,pharmacokinetic,and biologic study of semaxanib and thalidomide in patients with metastatic melanoma显示文摘 | Mita MM Rowinsky EK Forero L | 2007 | Cancer Chemother Pharmacol2007，59，2： | 1 |
| 11 | Safety,pharmacokinetics,and activity of ABX-EGF,a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer显示文摘 | Rowinsky EK Schwartz GH Gollob JA | 2004 | J Clin Oncol2004，22，15： | 1 |
| 12 | A phase Ⅱ trial of topotecan as salvage therapy in epithelial ovarian cancer 显示文摘 | Armstrong DK Rowinsky EK Donehower R | 1995 | Proc Am Soc Clin Oncol1995，14，： | 1 |
| 13 | The current status of camptothecin analoguesasant itumoragent 显示文摘 | SLICHEMYER WJ ROWINSKY EK DONEHOWER RC | 1993 | J Natl Cancer Inst1993，85，4： | 1 |
| 14 | Clinical foxicities encountered with paclitaxel 显示文摘 | Rowinsky EK Eisenhaucr EA Chaudhry V | 1993 | Sere Onclol1993，20，4： | 1 |
| 15 | Paclitaxel (taxol)显示文摘 | Rowinsky EK Donehower RC | 1995 | N Eng1 J Med1995，332，15： | 1 |
| 16 | A phase Ⅰ and pharmacokinetic study of SAM486A,a novel polyamine biosynthesis inhibitor,administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies显示文摘 | Siu LL Rowinsky EK Hammond LA | 2002 | Clin Cancer Res2002，8，7： | 1 |
| 17 | Signal events: Cell signal transduction and its inhibition in cancer 显示文摘 | Rowinsky EK | 2003 | Oncologist2003，8，3： | 1 |
| 18 | A phase I and pharmacokinetic study of pemetrexed plus irinotecanin patients with advanced solid malignancies显示文摘 | ROWINSKY EK BEERAM M HAMMOND LA et d | 2007 | Clin Cancer Res2007，13，2： | 1 |
| 19 | Phase Ⅰ and pharmacokinetic study of paclitaxel in combination with biricodar,a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP 显示文摘 | Rowinsky EK Smith L Wang YM | 1998 | J Clin Oncol1998，16，9： | 1 |
| 20 | The status of camptothecin analogues as antitumer agents 显示文摘 | Slichenmyer WJ rowinsky EK Donehower RC | 1993 | J National Cancer Intitute1993，85，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员